Last checked at 
(Alliance News) - Braveheart Investment Group PLC on Thursday reported several updates from its strategic investments.
Paraytec Ltd, which Braveheart wholly owns, said the second round of end user trials for the development of instruments for measuring protein aggregation in biopharmaceuticals is underway.
Protein aggregation is when mis-folded proteins accumulate and clump together, a phenomenon which is implicated in several diseases including Alzheimer's, Parkinson's and prion diseases.
Pharm 2 Farm Ltd, in which Braveheart has a 52% stake, has produced a batch of silicon micro-nutrient for shipment to customers in the Australian hydroponics market. Silicon is used to improve nutrient uptake and strengthen plants against disease, drought and other plant stresses.
Kirkstall Ltd, a biotech firm working in the organ-on-a-chip market and 65% investee of Braveheart, has appointed new distributors in South Korea and China. The distributors are currently undergoing product training which promotional plans for 2020 being finalised.
Sentinel Medial Ltd, a 38% investee, is continuing work with the University of Sheffield for optimising test protocols before restarting the testing of bladder cancer patient samples, while 21% investee Phasefocus Holdings Ltd continued to expands its vendor network.
To this end, Phasefoces has signed distribution agreement in the last three months with partners in Italy, Canada, Japan, France and Israel. These appointments are expected to extend the company's global presence and drive sales growth in its Livecyte live cell analysis product line.
Shares in Braveheart Investment were untraded on Friday, last quoted at 10.00 pence in London.
By Dayo Laniyan; dayolaniyan@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.